

Substitute Form PTO-1449 (Modified)  <b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)  (37 CFR §1.98(b))	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 21865-0002001	Application No. 10/718,986
	Applicant Yu et al.		
	Filing Date November 21, 2003	Group Art Unit 1652	

### U.S. Patent Documents

Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	1	2005/0112751	5/26/2005	Fang et al			
	2	2007/0190163	8/16/2007	Malaknov, M.P. et al.			
	3	2008/0075708	3/27/2008	Yu et al.			
	4	2009/0142327	6/4/2009	Fang et al			
	5						
	6						
	7						
	8						
	9						
	10						

### Foreign Patent Documents or Published Foreign Patent Applications

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	11	WO93/03708	3/4/1993	WIPO				
	12	WO98/31817	7/23/1998	WIPO				
	13							
	14							
	15							

### Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
	16	Ada et al., "Purification and properties of neuraminidase from <i>Vibrio cholerae</i> . <i>J Gen Microbiol</i> 24:409 (1961).
	17	Benet et al., <i>Pharmacological Basis of Therapeutics</i> , 8th ed., Eds. Goodman and Gillman, page 1-32, (1990).
	18	Cardin et al., "Molecular modeling of protein-glycosaminoglycan interactions." <i>Arteriosclerosis</i> 9:21-32 (1989).
	19	Cechechi et al., "Heparan sulfate glycosaminoglycans are receptors sufficient to mediate the initial binding of adenovirus types 2 and 5." <i>J Virol</i> 75:8772-80 (2001).
	20	Crennell et al., "Crystal structure of a bacterial sialidase (from <i>Salmonella typhimurium</i> LT2) shows the same fold as an influenza virus neuraminidase." <i>Proceedings of the National Academy of Sciences of the United States of America</i> 90:9852-9856 (1993).

Examiner Signature

Date Considered

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 21865-0002001	Application No. 10/718,986
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)		Applicant Yu et al.	
		Filing Date November 21, 2003	Group Art Unit 1652
(37 CFR §1.98(b))			

<b>Other Documents (include Author, Title, Date, and Place of Publication)</b>		
Examiner Initial	Desig. ID	Document
	21	Ernst et al., "Enzymatic degradation of glycosaminoglycans." <i>Critical Rev Biochem Mol Bio</i> 30:387-444 (1995).
	22	Finlay and Falkow, "Common Themes in Microbial Pathogenicity," <i>Microbiological Reviews</i> , 210-230 (1989).
	23	Granoff & Webster, R. G., ed. <i>Encyclopedia of Virology, 2<sup>nd</sup> Edition</i> , Vol 2.
	24	Guibinga et al., "Cell surface heparin sulfate is a receptor for attachment of envelope protein-free retrovirus-like particles and VSV-G pseudotyped MLV-derived retrovirus vectors to target cells." <i>Molecular Therapeutics</i> 5:538-46 (2002).
	25	Ishibashi et al., "Probiotics and safety," <i>The American Journal of Clinical Nutrition</i> 73: 465S-470S (2001)
	26	Jones et al., <i>Journal of Neuropathology and Experimental Neurology</i> 57(2): 140-157 (1998).
	27	Loomes et al., "Erythrocyte receptors for Mycoplasma pneumoniae are sialylated oligosaccharides of Ii antigen type", <i>Nature</i> 307:560-563 (1994).
	28	Loveless et al., "Sialo-Oligosaccharide Receptors for Mycoplasma pneumoniae and Related Oligosaccharides of Poly-N-Acetylactosamine Series Are Polarized at the Cilia and Apical-Microvillar Domains of the Ciliated Cells in Human Bronchial Epithelium" <i>Infection and Immunity</i> 57(4):1285-1289 (1989)
	29	MacEachran et al., "Adhesion of Pseudomonas aeruginosa to human buccal epithelial cells: evidence for two classes of receptors", <i>Canadian J. Microbiol.</i> 31:563-569 (1985).
	30	Marcus et al. "Adherence of Pseudomonas aeruginosa to Tracheal Epithelium", <i>Infection and Immunity</i> . 57:1050-1053 (1989).
	31	Meuller T.D., et al., "Structure, binding and antagonists in the IL-4/IL-13 receptor system. <i>Biochimica et Biophysica Acta</i> 1592:237-250 (2002).
	32	NCBI Protein AAH09799 (3 pgs.) (accessed on 09.19.2007)
	33	Neumann, G., et al., "Generation of Influenza A viruses entirely from cloned cDNAs." <i>Proceedings of the National Academy of Sciences of the United States of America</i> 96:9345-9350 (1999).
	34	Plowman, G. D., "The Amphiregulin Gene Encodes a Novel Epidermal Growth Factor-Related Protein with Tumor-Inhibitory Activity," <i>Molecular and Cellular Biology</i> 10(5):1969-1981 (1990).
	35	Powell et al., Attachment of Mycoplasma pneumoniae to Respiratory Epithelium., <i>Infection and Immunity</i> 13(3):959-966 (1976).
	36	Roberts et al., "Regulation of Lymphocyte Proliferation After Influenza Virus Infection of Human Mononuclear Leukocytes", <i>Journal of Medical Virology</i> , 27:179-187 (1989).
	37	Sobeslavsky et al., "Adsorption of Mycoplasma pneumoniae to Neuraminic Acid Receptors of Various Cells and Possible Role in Virulence," <i>Journal of Bacteriology</i> 96(3):695-705 (1968).
	38	Suzuki et al., "Receptor Specificities of Human Respiroviruses", <i>Journal of Virology</i> 75(10):4604-4613 (2001).
	39	Thorne, et al., "The Heparin-Binding Domain of Amphiregulin Necessitates the Precursor Pro-Region for Growth Factor Secretion," <i>Mol. Cell. Biol.</i> , 14:1635-1646 (1994)
	40	Umeda et al., "Activity of Human Erythrocyte Gangliosides as a Receptor to HVJ", <i>Virology Vol.</i> 133:172-182 (1984).
	41	Vishwanath et al., "Tracheobronchial Mucin Receptor for Pseudomonas aeruginosa: Predominance of Amino Sugars in Binding Sites", <i>Infection and Immunity</i> 48:331-335 (1985).
Examiner Signature		Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		

Substitute Form PTO-1449 (Modified)  <b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)  (37 CFR §1.98(b))	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 21865-0002001	Application No. 10/718,986
		Applicant Yu et al.	
		Filing Date November 21, 2003	Group Art Unit 1652

**Other Documents (include Author, Title, Date, and Place of Publication)**

Examiner Initial	Desig. ID	Document
	42	Vlasak et al., "Human and bovine coronaviruses recognize sialic acid-containing receptors similar to those of influenza C viruses," <i>Proceedings of the National Academy of Sciences of the United States of America</i> 85:4526-4529 (1988).
	43	Wills-Karp et al., "Interleukin-13 in asthma." <i>Curr Opin Pulm Med</i> 9:21-27 (2003).
	44	Wybenga et al., "Glycophorin as a Receptor for Sendai Virus", <i>Biochemistry</i> 35:9513-9518 (1996).
	45	Non-final Office action dated 4/21/2009 for U.S. Application Serial No. 10/939,262.
	46	Final Office action dated 10/24/2008 for U.S. Application Serial No. 10/939,262.
	47	Non-final Office action dated 3/26/2008 for U.S. Application Serial No. 10/939,262.
	48	Non-final Office action dated 5/22/2007 for U.S. Application Serial No. 10/939,262.
	49	Non-final Office action dated 12/18/2008 for U.S. Application Serial No. 11/893,621.

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	